ASGCT 2027 Annual Meeting: What to Know About Gene and Cell Therapy's Flagship Scientific Gathering

The American Society of Gene & Cell Therapy (ASGCT) will hold its 2027 Annual Meeting May 4–8, 2027, at the Pennsylvania Convention Center in Philadelphia. It's one of the field's most important yearly gatherings, bringing together the researchers, clinicians, and regulators actively shaping where stem cell and gene therapy research goes next. Here's what the meeting is, why it matters, and what to watch for as 2027 approaches.

What ASGCT Is, and Why Its Meeting Matters

ASGCT is the leading professional society for the gene and cell therapy field, representing researchers, clinicians, and institutions working across gene editing, viral and non-viral delivery systems, CAR-T and other engineered cell therapies, and stem cell-based regenerative medicine. Its Annual Meeting is the field's largest dedicated scientific conference, drawing thousands of attendees each year — academic scientists presenting new preclinical and clinical data, physicians running trials, biotech and pharmaceutical companies, and FDA and other regulators who participate in dedicated sessions on the evolving approval pathway for these therapies. For a field that spans everything from CRISPR gene editing to stem cell-derived cell transplants, ASGCT's meeting functions as the year's central checkpoint: where the newest trial results, safety data, and manufacturing advances get presented and debated together in one place, often well before they appear in a published paper.

What to Expect at the 2027 Meeting

ASGCT's annual meetings consistently cover a broad swath of the field through parallel scientific tracks, late-breaking abstract sessions, and plenary talks from leading investigators. Based on the consistent structure of recent ASGCT meetings — including the 2026 meeting held in Boston — the 2027 program in Philadelphia is expected to include sessions spanning gene editing and genome engineering, viral and non-viral vector delivery, CAR-T and other engineered immune cell therapies, stem cell and regenerative medicine research, manufacturing and quality control (CMC) challenges unique to living cell products, and regulatory and policy sessions addressing how agencies like the FDA are adapting their frameworks to keep pace with this fast-moving field. ASGCT typically also hosts an exhibit hall where companies showcase new platforms and partnership opportunities, along with networking and early-career events. Specific 2027 session titles, confirmed speakers, and the abstract submission timeline are set closer to the meeting and will be posted on ASGCT's own event page as they're finalized.

Who Attends, and Why a General Reader Might Care

While the meeting is built for working scientists and clinicians, its ripple effects reach anyone following where stem cell and gene therapy treatments are headed. Data presented at ASGCT often previews results that later show up in FDA approval decisions, peer-reviewed publications, or new clinical trials recruiting patients — which means the meeting is frequently the earliest public glimpse at where the field's genuine progress, and its real remaining obstacles, actually stand. Regulatory sessions in particular can signal how the FDA's thinking on evidentiary standards for these therapies is evolving, which matters directly to how quickly legitimate new treatments can reach patients.

How to Learn More

Readers interested in following the 2027 meeting can check ASGCT's official events page for registration details, the released scientific program, and abstract deadlines as they're published in the lead-up to May 2027.

Bottom Line

ASGCT's Annual Meeting is a genuinely significant fixture on the cell and gene therapy calendar — a place where real scientific progress, including in stem cell-based regenerative medicine, gets presented, scrutinized, and discussed in the open. The 2027 meeting's dates and Philadelphia location are confirmed; the specific science on display will become clearer as the program is finalized over the coming months.